Mostra i principali dati dell'item
| dc.contributor.author | Rodríguez Sánchez, César Augusto | |
| dc.contributor.author | Martín Gómez, María Teresa | |
| dc.contributor.author | Lozano Mejorada, Rebeca | |
| dc.contributor.author | Gomez, Amalia | |
| dc.contributor.author | Cruz Hernández, Juan Jesús | |
| dc.date.accessioned | 2026-03-06T19:14:50Z | |
| dc.date.available | 2026-03-06T19:14:50Z | |
| dc.date.issued | 2017-08-27 | |
| dc.identifier.citation | Rodriguez, C. A., Martin, T., Lozano, R., Gomez, A., & Cruz, J. J. (2017). Spontaneous nasal perforation in a bevacizumab‐treated patient with metastatic breast cancer. The Breast Journal, 23(6), 745-746. | es_ES |
| dc.identifier.uri | http://hdl.handle.net/10366/170342 | |
| dc.description | Se trata de un caso clínico breve que describe la aparición de una perforación espontánea del tabique nasal en una paciente de 34 años con cáncer de mama metastásico, hormonosensible y HER2 negativo, tratada con paclitaxel y bevacizumab. La publicación pone el foco en una complicación infrecuente asociada a la terapia antiangiogénica, subrayando su interés clínico como efecto adverso raro pero relevante que conviene reconocer de forma precoz en la práctica oncológica | es_ES |
| dc.description.abstract | [EN]Nasal septum perforation in patients with cancer receiving systemic therapy is rare, and its association with bevacizumab use has described recently in the literature. Here, we report the case of a 34-year-old woman with hormone-sensitive, HER-2/neu negative, metastatic breast cancer who develope a nasal septum perforation during the treatment with paclitaxel and bevacizumab. | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | Wiley | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Bevacizumab | es_ES |
| dc.subject | Breast cancer | es_ES |
| dc.subject | Nasal septum perforation | es_ES |
| dc.subject.mesh | Breast Neoplasms | * |
| dc.subject.mesh | Nasal Septal Perforation | * |
| dc.subject.mesh | Lung Neoplasms | * |
| dc.subject.mesh | Neoplasm Metastasis | * |
| dc.subject.mesh | Adult | * |
| dc.subject.mesh | Diagnosis | * |
| dc.subject.mesh | Antibodies | * |
| dc.subject.mesh | Humans | * |
| dc.subject.mesh | Paclitaxel | * |
| dc.subject.mesh | Angiogenesis Inhibitors | * |
| dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | * |
| dc.title | Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer | es_ES |
| dc.type | info:eu-repo/semantics/article | es_ES |
| dc.relation.publishversion | https://doi.org/ 10.1111/TBJ.12913 | es_ES |
| dc.identifier.doi | 10.1111/tbj.12913 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
| dc.audience.educationLevel | ||
| dc.identifier.pmid | 28845572 | |
| dc.identifier.essn | 1524-4741 | |
| dc.journal.title | The breast journal | es_ES |
| dc.volume.number | 23 | es_ES |
| dc.issue.number | 6 | es_ES |
| dc.page.initial | 745 | es_ES |
| dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
| dc.subject.decs | adulto | * |
| dc.subject.decs | paclitaxel | * |
| dc.subject.decs | neoplasias pulmonares | * |
| dc.subject.decs | protocolos de quimioterapia antineoplásica combinada | * |
| dc.subject.decs | humanos | * |
| dc.subject.decs | perforación del tabique nasal | * |
| dc.subject.decs | metástasis neoplásica | * |
| dc.subject.decs | diagnóstico | * |
| dc.subject.decs | inhibidores de la angiogénesis | * |
| dc.subject.decs | neoplasias de la mama | * |
| dc.subject.decs | anticuerpos | * |








